Validity and Reliability of the Turkish Version of National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18) and Neurotoxicity-4 (NTX-4) for Patients with Advanced Ovarian Cancer

Table 4

Convergent validity of NFOSI-18 and NTX-4.

n = 94	Mobility	EQ-5D-3L
		Self-care	Usual activities	Pain/discomfort	Anxiety/depression	EQ-5D-3L total	VAS
NFOSI-18
DRS-physical	−0.540	−0.454	−0.608	−0.581	−0.489	0.671	0.745
DRS-emotional	−0.377	−0.366	−0.450	−0.394	−0.554	0.542	0.546
Treatment side effects	−0.306	−0.350	−0.517	−0.465	0.540	0.560	0.598
Function/well-being	−0.504	−0.470	−0.413	−0.516	−0.582	0.642	0.729
NFOSI-18 total	−0.608	−0.450	−0.571	−0.577	−0.594	0.648	0.779
NTX-4
NTX-1	−0.457	−0.379	−0.484	−0.462	−0.471	−0.569	0.543
NTX-2	−0.510	−0.338	−0.454	−0.489	−0.447	−0.574	0.556
NTX-3	−0.407	−0.313	−0.445	−0.519	−0.375	−0.527	0.501
NTX-4	−0.563	−0.342	−0.452	−0.544	−0.404	−0.597	0.506
NTX-4 total	−0.581	−0.391	−0.521	−0.584	−0.466	−0.694	0.527

r: Pearson correlation coefficient, n: number, NFOSI-18: the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index-18 Item Version, NTX-4: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity 4-item; EQ-5D-3L: European Quality of Life Survey-5 Dimensions-3 Levels, VAS: visual analogue scale, and DRS: disease-related symptom. r > 0.3 and  < 0.01.